Vermillion Wealth Management, Inc. Summit Therapeutics Inc. Transaction History
Vermillion Wealth Management, Inc.
- $370 Billion
- Q3 2025
A detailed history of Vermillion Wealth Management, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vermillion Wealth Management, Inc. holds 504 shares of SMMT stock, worth $9,107. This represents 0.0% of its overall portfolio holdings.
Number of Shares
504
Previous 504
-0.0%
Holding current value
$9,107
Previous $10.7 Million
2.91%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
269Shares Held
92.7MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$609 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$206 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$143 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$72.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$70.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...